Caredx, Inc.
A precision medicine company focused on keeping transplanted organs healthy. CareDx makes non-invasive blood tests — AlloMap Heart and the AlloSure Kidney, Heart, and Lung panels — that monitor transplant recipients for early signs of rejection without a biopsy, along with HLA typing kits and AlloSeq gene-sequencing tools used to match donors and recipients. Its Ottr and MedActionPlan software help transplant teams track and manage patient care between visits.
Granted 470.8K · Sold 124.4K
Granted 360.0K
Sold 5.6K
Granted 267.9K · Sold 265
Granted 62.5K · Sold 73.8K
Granted 235.5K · Sold 95.3K
Granted 245.9K
Granted 88.4K
Granted 185.9K
Granted 21.9K
Granted 63.8K · Sold 20.0K
Granted 60.5K · Sold 35.6K
Granted 82.9K
Granted 49.4K · Sold 49.4K
Granted 65.4K · Sold 45.8K
Granted 21.9K
Granted 12.1K · Sold 10.6K
Granted 37.2K
Granted 21.9K · Sold 22.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hanna John Walter JRPresident and CEO, Director · 21 transactions | — | 662.0K | 470.8K | — | 124.4K |
| Ronai AbrahamSee Remarks · 2 transactions | +232.5% | 516.0Kas of Sep 2023 | 360.0K | — | — |
| Seeto ReginaldSee Remarks, Director · 2 transactions | -1.2% | 479.2Kas of Oct 2023 | — | — | 5.6K |
| Jain AbhishekChief Financial Officer · 20 transactions | +142% | 319.7Kas of Aug 2025 | 267.9K | — | 265 |
| Maag PeterDirector · 15 transactions | -0.3% | 308.8Kas of Jul 2025 | 62.5K | — | 73.8K |
| Johnson Alexander LSee Remarks · 16 transactions | +62.5% | 306.5Kas of Aug 2024 | 235.5K | — | 95.3K |
| Kennedy KeithCFO & COO · 8 transactions | — | 221.5K | 245.9K | — | — |
| Goldberg MichaelDirector · 17 transactions | +102.2% | 195.7K | 88.4K | — | — |
| Meng JessicaChief Commercial Officer · 7 transactions | — | 169.4K | 185.9K | — | — |
| Cohen Fred EDirector · 2 transactions | +466.5% | 165.1K | 21.9K | — | — |
| Bickerstaff GeorgeDirector · 7 transactions | +61.7% | 154.1K | 63.8K | — | 20.0K |
| Novack Jeffrey AdamSecretary and General Counsel · 37 transactions | — | 112.6K | 60.5K | — | 35.6K |
| Smith NathanChief Financial Officer · 4 transactions | — | 75.0K | 82.9K | — | — |
| Hagstrom William ADirector · 7 transactions | +151.8% | 73.4Kas of Jun 2025 | 49.4K | — | 49.4K |
| Cournoyer ChristineDirector · 8 transactions | +102.3% | 58.9K | 65.4K | — | 45.8K |
| Riggsbee Richard BryanDirector · 2 transactions | — | 39.3K | 21.9K | — | — |
| Torres Arthur ADirector · 3 transactions | +32.7% | 38.7K | 12.1K | — | 10.6K |
| Gunasekaran SureshDirector · 2 transactions | — | 37.2K | 37.2K | — | — |
| Valantine HannahDirector · 4 transactions | +25.9% | 36.7K | 21.9K | — | 22.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -483.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.